Xintela: Taking position for the next phase - VH Corp
• Encouraging interim results with XSTEM OA • EQGen licensing deal signed regarding EQSTEM • Our fair value amounts to SEK 1.49 per share
ANNONS
During the spring Xintela announced positive interim data from its phase I/IIa study with XSTEM in knee ostoearthritis. The company also signed a license and collaboration agreement wtih EQGen Biomedical regarding EQSTEM. Despite the advances, Xintela's financial situation remains challenging. The company reported cash holdings of MSEK 6.4 by the end of Q1. Most likely, the company will receive proceeds from the warrant TO3, the last exercise period is ongoing. If fully subscribed, TO3 could add MSEK 11. Xintela is also awaiting the upfront fee of MSEK 1 from EQGen.
Our model suggests a fair value of SEK 1.49 per share.
